All In Biotech

Drug Trial Radar · NCT07037771

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

70

Actual

Start

Jun 17, 2025

Primary completion

Aug 20, 2027

Study completion Aug 20, 2027

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • zodasiran InjectionDrug

    ARO-ANG3 Injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)Time frame: Baseline, Month 12

Locations

43 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site 7

    Park Ridge, Illinois

  • Research Site 2

    New York, New York

  • Research Site 1

    Cincinnati, Ohio

  • Research Site 14

    Pittsburgh, Pennsylvania

  • Research Site 13

    Camperdown, New South Wales, Australia

  • Research Site 9

    Saint Leonards, New South Wales, Australia

  • Research Site 21

    Heidelberg, Victoria, Australia

  • Research Site 3

    Nedlands, Western Australia, Australia

  • Research Site 40

    Innsbruck, Austria

  • Research Site 39

    Linz, Austria

  • Research Site 42

    Vienna, Austria

  • Research Site 37

    Vienna, Austria

  • Research Site 33

    La Louvière, Belgium

  • Research Site 34

    Leuven, Belgium

  • Research Site 24

    Cerqueira César, São Paulo, Brazil

  • Research Site 4

    Québec, Canada

  • Research Site 5

    Vancouver, British Columbia, Canada

  • Research Site 6

    Chicoutimi, Quebec, Canada

  • Research Site 30

    Hradec Králové, Czechia

  • Research Site 23

    Paris, France

  • Research Site 17

    Tbilisi, Georgia

  • Research Site 18

    Tbilisi, Georgia

  • Research Site 19

    Tbilisi, Georgia

  • Research Site 35

    Berlin, Germany

  • Research Site 10

    Jerusalem, Israel

  • Research Site 15

    Tel HaShomer, Israel

  • Research Site 20

    Fukushima, Japan

  • Research Site 16

    Okayama, Japan

  • Research Site 22

    Saitama, Japan

  • Research Site 25

    Tokyo, Japan

  • Research Site 26

    Kanazawa, Ishikawa-ken, Japan

  • Research Site 27

    Suita, Osaka, Japan

  • Research Site 12

    Christchurch, New Zealand

  • Research Site 31

    Riyadh, Saudi Arabia

  • Research Site 8

    Cape Town, South Africa

  • Research Site 11

    Parktown, Johannesburg, South Africa

  • Research Site 43

    Barcelona, Spain

  • Research Site 28

    Córdoba, Spain

  • Research Site 29

    Madrid, Spain

  • Research Site 32

    Gothenburg, Sweden

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.